Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Stephan Herbertz,1 J Scott Sawyer,2 Anja J Stauber,2 Ivelina Gueorguieva,3 Kyla E Driscoll,4 Shawn T Estrem,2 Ann L Cleverly,3 Durisala Desaiah,2 Susan C Guba,2 Karim A Benhadji,2 Christopher A Slapak,2 Michael M Lahn21Lilly Deutschland GmbH, Bad Homburg, Germany; 2Lilly Research Laboratori...

Full description

Bibliographic Details
Main Authors: Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM
Format: Article
Language:English
Published: Dove Medical Press 2015-08-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/clinical-development-of-galunisertib-ly2157299-monohydrate-a-small-mol-peer-reviewed-article-DDDT

Internet

http://www.dovepress.com/clinical-development-of-galunisertib-ly2157299-monohydrate-a-small-mol-peer-reviewed-article-DDDT

Similar Items